The US Food and Drug Administration (FDA) has announced it will re-evaluate the regulatory status of several widely discussed therapeutic peptides, including BPC-157, KPV and Semax
Media reports have also flagged Sikiris commercial interest in BPC-157, noting that his patent for a stable version of the compound is for sale
Several Substances Get Placed on the Category 2 Bulks List The following substances were added to Category 2 because FDA claimed to identify significant safety risks: AOD 9604 BPC-157 Cathelicidin LL-37 CJC-1295 Dihexa Acetate Emideltide (DSIP) Epitalon GHK-Cu (for injectable routes of administration) Ibutamoren Mesylate Ipamorelin Acetate Kisspeptin-10 KPV Melanotan II Mechano Growth Factor, Pegylated (PEG-MGF) MOTs-C Selank Acetate (TP-7) Semax (heptapeptide) Thymosin Alpha-1 (Ta1) Thymosin Beta-4, Fragment (LKKTETQ) Compounding Industry Group Initial Response In early October, Scott Brunner from the Alliance for Pharmacy Compounding (APC) commented on the updates, particularly noting the addition of certain peptides to Category 2
Track reconstitution and disposal dates
Document what was assessed, what clinical decision was made, and how that decision differed from the injection administration work
Clinical trials have shown: Reduced neuropathic pain Improved nerve fiber density Better sensory function Importantly, these benefits occurred without changes in hemoglobin or hematocrit
&srotate=0)
